In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

(Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers ...

Highlights,Bristol-Myers Squibb manages its debt effectively with solid earnings.,A substantial cash reserve supports the ...

We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

Shares of Exelixis, Inc. EXEL have surged 50% in a year against the industry’s decline of 16.1%. The stock has also ...

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14.

If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Filling your portfolio with dividend-paying stocks that raise their quarterly ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of some unusual options trading on Thursday. Investors purchased 296,826 call options on the stock. This represents an increase of 866% ...